Plant Name: Artemisia scoparia
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.031E-13 | 5.529E-10 | BLM, CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, MMP1, MMP2, MMP9, PTPN1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.545E-08 | 5.514E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.767E-07 | 2.405E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.241E-07 | 2.572E-04 | BLM, CA2, CA9, CASP1, CASP7, CSNK2A1, CYP1A2, ESR1, MAPK1, NFKB1, TRPA1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.229E-27 | 2.676E-23 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.927E-06 | 1.399E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.927E-06 | 1.399E-03 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 4.396E-06 | 2.901E-03 | ESR1, ESR2 |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 9.845E-06 | 5.878E-03 | AKR1B1, ALOX15, BLM, CA2, CA9, HIF1A, LMNA, MAPK1, MAPT, MMP9, NFKB1, PTPN1, TDP1 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.215E-05 | 6.616E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.272E-05 | 6.753E-03 | AKR1B1, AKR1B10, CYP1A2, CYP2C9, CYP3A4, ESR1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.317E-05 | 6.828E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 1.750E-05 | 8.660E-03 | AKR1B1, BLM, CASP7, MAPK1, MMP2, NFKB1, TSHR |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.626E-21 | 7.214E-17 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.380E-19 | 7.513E-16 | CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.579E-27 | 1.099E-24 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14; CA13 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.478E-07 | 2.521E-05 | CYP2C9; CYP1A2; ALOX15; CYP3A4 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.457E-06 | 6.330E-05 | MMP1; MMP2; MAPK1; MMP9 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.746E-06 | 6.330E-05 | MMP2; MAPK1; ESR1; MMP9; ESR2 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.414E-05 | 3.416E-04 | MAPK1; ESR1; NFKB1; ESR2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.399E-06 | 2.726E-04 | CYP2C9; CYP1A2; ALDH1A1; CYP3A4 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.374E-05 | 9.199E-04 | MMP2; PIM1; MAPK1; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 5.710E-05 | 9.199E-04 | MMP2; MAPK1; HIF1A; ESR1; MMP9 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.663E-05 | 3.444E-04 | CASP7; CASP1; MAPK1; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.471E-04 | 1.778E-03 | MMP1; MMP2; MAPK1; HIF1A; MMP9; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.499E-05 | 1.060E-03 | CASP7; MAPK1; MMP9; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 8.044E-05 | 1.060E-03 | CYP2C9; ALOX15; MAPK1; PTGS1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.905E-04 | 1.963E-03 | CASP7; LMNA; MAPK1; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.167E-04 | 1.963E-03 | PIM1; MAPK1; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.948E-04 | 1.963E-03 | CASP7; CASP1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 3.818E-04 | 2.913E-03 | CASP7; MAPK1; MAPT; HSD17B10 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.780E-04 | 2.372E-03 | CYP2C9; ALOX15; PTGS1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.167E-04 | 1.963E-03 | CASP1; MAPK1; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 7.532E-04 | 4.551E-03 | CYP2C9; AKR1B10; CYP1A2; ALOX15; ALDH1A1; AKR1B1; CYP3A4; HSD17B10; PTGS1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.814E-04 | 2.913E-03 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 4.685E-04 | 3.235E-03 | PTPN1; CSNK2A1; MAPK1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.502E-04 | 3.235E-03 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.227E-03 | 7.115E-03 | MAPK1; HIF1A; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.328E-04 | 4.171E-03 | CYP2C9; CYP1A2; CYP3A4 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 7.272E-04 | 4.551E-03 | CASP1; MAPK1; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.812E-03 | 9.733E-03 | MAPK1; ESR1; HIF1A |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.132E-03 | 1.465E-02 | PIM1; MAPK1; MMP9; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.902E-03 | 9.780E-03 | ADORA3; MAPK1; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.316E-03 | 1.503E-02 | MAPK1; MMP9; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 5.500E-03 | 2.417E-02 | CASP1; MAPK1; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 7.834E-03 | 2.795E-02 | MAPK1; NFKB1; TSHR |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.887E-03 | 2.511E-02 | TSHR; PTGS1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 6.732E-03 | 2.638E-02 | MAPK1; HIF1A |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.529E-02 | 4.346E-02 | MAPK1; MAPT; NFKB1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 6.516E-03 | 2.624E-02 | AKR1B10; AKR1B1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 8.095E-03 | 2.795E-02 | MAPK1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 8.095E-03 | 2.795E-02 | MAPK1; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 9.829E-03 | 3.032E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 9.829E-03 | 3.032E-02 | MAPK1; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.435E-02 | 4.246E-02 | MAPK1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.496E-02 | 4.340E-02 | MMP2; MAPK1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 8.333E-03 | 2.810E-02 | MAPK1; HIF1A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.303E-03 | 2.611E-02 | CYP1A2; CYP3A4 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.822E-02 | 4.984E-02 | MAPK1; HIF1A |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 7.628E-03 | 2.795E-02 | CASP1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 9.829E-03 | 3.032E-02 | MAPK1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 7.860E-03 | 2.795E-02 | MAPK1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 9.318E-03 | 3.032E-02 | CA2; CYP3A4 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.559E-02 | 4.348E-02 | CSNK2A1; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.720E-03 | 9.592E-03 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.472E-03 | 1.195E-02 | AKR1B10; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.956E-03 | 9.780E-03 | AKR1B10; AKR1B1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.021E-02 | 3.084E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; CA1; CA1; AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; AKR1B1; CASP1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; ESR1; ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; AKR1B1 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; PTGS1 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | TRPA1; ESR1; PTGS1 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; PTGS1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; MMP2; PTGS1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CA9; MAPK1; MMP9; MMP2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; HIF1A; CA1; CA9; MAPK1; MMP9; NFKB1; ESR1; ESR1; PIM1; MMP2; CSNK2A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |